Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Johnson & Johnson

Final Analysis Show Johnson & Johnson's COVID-19 Offers Only 52.9% Protection

Scientists have revealed data from their final analysis of Johnson & Johnson's (NYSE: JNJ) COVID-19 Phase 3 study, showing the vaccine may be even less effective in the longer term.

Benzinga

Johnson & Johnson Halts Production Of Its COVID-19 Vaccine: NYT

Johnson & Johnson (NYSE: JNJ) quietly shut down the only plant making usable batches of its COVID-19 vaccine, the

Benzinga

J&J may be forced to stop selling talc in UK as cancer court cases continue

"Various studies have shown a link between using talcum powder between the legs and ovarian cancer."

Wales Online

From analysis to the latest developments in health,
read the most diverse news in one place.

Johnson & Johnson faces push to force global ban on talc baby powder sales

Move to hold shareholder vote follows withdrawal of product in US and Canada and lawsuits alleging link to cancer cases

The Guardian - UK

Hopeful Golden Cross Forms On Johnson & Johnson's Chart

If history is any guide, there may be good fortune ahead for shares of Johnson & Johnson (NYSE:JNJ). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be bullish for the stock.

Benzinga

Covid rules on travelling to different countries around Europe

Here's everything you need to know about vaccination status and testing process in countries such as France, Austria, Switzerland and Italy

Wales Online

Johnson & Johnson recipients can get third COVID shot in San Francisco

SAN FRANCISCO — San Francisco health officials are allowing people who originally got the Johnson & Johnson COVID-19 vaccine to get a second booster shot — which would give them access to the same number of doses currently available to recipients of Pfizer-BioNTech or Moderna.

Los Angeles Times

Read news from The Economist, FT, and more,
with one subscription

Johnson & Johnson, Distributors Reach $590M Opioid Settlement For Tribe Claims: Report

Johnson & Johnson (NYSE: JNJ) and the three U.S.

Benzinga

Native American tribes reach $590M opioid settlement with Johnson & Johnson and distributors

It's the largest opioid settlement for Native Americans.

Axios

Johnson & Johnson Whale Trades Spotted

Someone with a lot of money to spend has taken a bearish stance on Johnson & Johnson (NYSE:JNJ). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

Cramer's Mad Money Recap 1/26: Microsoft, Johnson & Johnson, IBM

Jim Cramer says investors need to protect themselves in a market where the Fed is no longer their friend.

The Street

This Is What Whales Are Betting On Johnson & Johnson

Someone with a lot of money to spend has taken a bullish stance on Johnson & Johnson (NYSE:JNJ). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

Mid-Morning Market Update: Markets Open Lower; Johnson & Johnson Sales Miss Views

Following the market opening Tuesday, the Dow traded down 1.79% to 33,748.82 while the NASDAQ fell 2.56% to 13,499.97. The S&P also fell, dropping, 2.59% to 13,496.29.

Benzinga

Johnson & Johnson Expects At Least $3 Billion In Sales Of Its Underdog Covid Shot

Johnson & Johnson expects at least $3 billion in sales of its Covid vaccine this year, and JNJ stock ticked higher Tuesday.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Johnson & Johnson's FY21 COVID-19 Vaccine Sales Below Expectations

Johnson & Johnson (NYSE: JNJ)

Benzinga

Johnson & Johnson: Q4 Earnings Insights

Johnson & Johnson (NYSE:JNJ) reported its Q4 earnings results on Tuesday, January 25, 2022 at 06:30 AM. Here's what investors need to know about the announcement.

The Street

Johnson & Johnson Tops Q4 Earnings Forecast, Sees $3.5 Billion in 2022 Covid Vaccine Sales

Johnson & Johnson topped the Street's Q4 earnings forecast, but fell modestly shy on revenues even as it sees Covid vaccine sales rising to $3.5 billion this year.

Benzinga

5 Stocks To Watch For January 25, 2022

Some of the stocks that may grab investor focus today are: Wall Street expects Johnson & Johnson (NYSE: JNJ) to report quarterly earnings at $2.12 per share on revenue of $25.29 billion before the opening bell. Johnson & Johnson shares fell 0.3% to $162.50 in after-hours trading.

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Johnson & Johnson's Earnings: A Preview

Johnson & Johnson (NYSE:JNJ) is set to give its latest quarterly earnings report on Tuesday, 2022-01-25. Here's what investors need to know before the announcement. Analysts estimate that Johnson & Johnson will likely report an Earnings Per Share (EPS) of $2.12.

Asharq Al-Awsat

Hajj, Umrah Ministry Exempts Immunized with Approved Vaccines from Quarantine

Saudi Arabia’s Ministry of Hajj and Umrah has decided that travelers inbound to the Kingdom who have received a full dose of one of the approved vaccines, including Oxford-AstraZeneca, Pfizer-BioNTech, Johnson & Johnson, Moderna, are exempt from the need to quarantine. In a statement to Asharq Al-Awsat, the Ministry revealed…

1 2

People

Jim Cramer

459 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Ministry of Hajj and Umrah

15 stories

J&J

13 stories

Read news from The Economist, FT, and more,
with one subscription

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.